FIELD : medicine; pharmaceuticals.SUBSTANCE : present invention describes a composition, methods and a kit for treating inflammatory bowel disease (IBD), such as Crohn' s disease and ulcerative colitis in a mammal in need of such treatment. Described method involves the use of a combined therapy comprising a therapeutically effective amount of chemokine receptor 9 (CCR9) inhibitor to an IBD patient, and a therapeutically effective amount of an antibody blocking α4β7-integrin, which is vedolizumab or antibodies directed against TNFα. Disclosed pharmaceutical composition and kit contain a CCR9 inhibitor and the above blocking antibody α4β7 integrin. Present CCR9 inhibitor is a compound having the following structural formula or a pharmaceutically acceptable salt thereof.EFFECT : invention provides treatment of inflammatory bowel disease, such as Crohn' s disease and ulcerative colitis.11 cl, 12 dwg, 1 ex